scholarly journals Plasma 25-Hydroxyvitamin D Levels and VDR Gene Expression in Peripheral Blood Mononuclear Cells of Leukemia Patients and Healthy Subjects in Central Kazakhstan

Nutrients ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1229
Author(s):  
Assel G. Zhumina ◽  
Konstantin Li ◽  
Anna A. Konovalova ◽  
Yelena A. Li ◽  
Margarita Yu. Ishmuratova ◽  
...  
Keyword(s):  
Gene Expression ◽  
Vitamin D ◽  
Healthy Subjects ◽  
Mononuclear Cells ◽  
Vdr Gene ◽  
Peripheral Blood Mononuclear ◽  
Hydroxyvitamin D ◽  
Blood Mononuclear Cells ◽  
25 Hydroxyvitamin D ◽  
Gene Expression Levels

Low blood levels of the vitamin D metabolite 25-hydroxyvitamin D [25(OH)D] have been associated with an increased risk and poorer outcomes of various cancers, including hematological malignancies. The Central Kazakhstan area has a relatively high incidence rate of leukemia. However, the relationship between vitamin D status and leukemia or other types of cancer in Kazakhstan has not yet been addressed. Therefore, in this first pilot single-center study conducted in Central Kazakhstan, we compared plasma levels of 25(OH)D and the vitamin D receptor (VDR) gene expression levels in peripheral blood mononuclear cells of patients with leukemia and demographically matching healthy volunteers. The levels of 25(OH)D in patients were found to be significantly lower (10.8 ± 7.0 ng/mL; n = 31) than in healthy subjects (21.6 ± 7.8 ng/mL; n = 34; p < 0.0001). A similar difference was observed in both younger (<60 years old) and older (>60 years old) participants, though there was no association between 25(OH)D concentration and age within the patient group. In female patients, 25(OH)D levels were significantly lower than in male patients (p = 0.04). No significant seasonal variations of 25(OH)D were observed in either the patient or the control group. VDR gene expression levels appeared to be similar in leukemia patients and healthy subjects, and no correlation between the cellular VDR expression and plasma 25(OH)D concentrations was observed in either group of participants. We did not observe a significant association of 25(OH)D or VDR levels and overall survival of leukemia patients. This observational study conducted for the first time in Kazakhstan supports previous findings demonstrating reduced blood 25(OH)D levels in cancer (leukemia) patients. Larger studies are required to determine whether low 25(OH)D plasma concentrations represent a risk factor for leukemia development and/or progression.

scholarly journals Age, serum 25-hydroxyvitamin D and vitamin D receptor (VDR) expression and function in peripheral blood mononuclear cells

Oncotarget ◽  
2016 ◽  
Vol 7 (24) ◽  
pp. 35512-35521 ◽  
Author(s):  
Laura A. Coleman ◽  
Margarita Mishina ◽  
Mark Thompson ◽  
Sarah M. Spencer ◽  
Adrian J. Reber ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Receptor ◽  
Peripheral Blood Mononuclear Cells ◽  
Peripheral Blood ◽  
Mononuclear Cells ◽  
Peripheral Blood Mononuclear ◽  
Hydroxyvitamin D ◽  
Blood Mononuclear Cells ◽  
25 Hydroxyvitamin D ◽  
And Function

scholarly journals Immunologic Effects of Vitamin D on Human Health and Disease

Nutrients ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 2097 ◽  
Author(s):  
Nipith Charoenngam ◽  
Michael F. Holick
Keyword(s):  
Vitamin D ◽  
Mononuclear Cells ◽  
Human Peripheral Blood ◽  
Active Form ◽  
Experimental Studies ◽  
Vitamin D Supplementation ◽  
Peripheral Blood Mononuclear ◽  
Hydroxyvitamin D ◽  
Increased Risk ◽  
25 Hydroxyvitamin D

Vitamin D is responsible for regulation of calcium and phosphate metabolism and maintaining a healthy mineralized skeleton. It is also known as an immunomodulatory hormone. Experimental studies have shown that 1,25-dihydroxyvitamin D, the active form of vitamin D, exerts immunologic activities on multiple components of the innate and adaptive immune system as well as endothelial membrane stability. Association between low levels of serum 25-hydroxyvitamin D and increased risk of developing several immune-related diseases and disorders, including psoriasis, type 1 diabetes, multiple sclerosis, rheumatoid arthritis, tuberculosis, sepsis, respiratory infection, and COVID-19, has been observed. Accordingly, a number of clinical trials aiming to determine the efficacy of administration of vitamin D and its metabolites for treatment of these diseases have been conducted with variable outcomes. Interestingly, recent evidence suggests that some individuals might benefit from vitamin D more or less than others as high inter-individual difference in broad gene expression in human peripheral blood mononuclear cells in response to vitamin D supplementation has been observed. Although it is still debatable what level of serum 25-hydroxyvitamin D is optimal, it is advisable to increase vitamin D intake and have sensible sunlight exposure to maintain serum 25-hydroxyvitamin D at least 30 ng/mL (75 nmol/L), and preferably at 40–60 ng/mL (100–150 nmol/L) to achieve the optimal overall health benefits of vitamin D.

1,25-Dihydroxyvitamin D increases the gene expression of enzymes protecting from glucolipotoxicity in peripheral blood mononuclear cells and human primary endothelial cells

2016 ◽  
Vol 7 (6) ◽  
pp. 2537-2543 ◽  
Author(s):  
Katarina Kuricova ◽  
Anna Pleskacova ◽  
Lukas Pacal ◽  
Katerina Kankova
Keyword(s):  
Gene Expression ◽  
Vitamin D ◽  
Endothelial Cells ◽  
Mononuclear Cells ◽  
Peripheral Blood Mononuclear ◽  
Dihydroxyvitamin D ◽  
1,25 Dihydroxyvitamin D ◽  
Blood Mononuclear Cells ◽  
Classical Function ◽  
Calcium And Phosphorus

Besides its classical function as an orchestrator of calcium and phosphorus homeostasis, vitamin D also affects insulin secretion and tissue efficiency.

scholarly journals Assessment of Wnt pathway selected gene expression levels in peripheral blood mononuclear cells (PBMCs) of postmenopausal patients with low bone mass

2020 ◽  
Author(s):  
Michal Stuss ◽  
Monika Migdalska-Sęk ◽  
Ewa Brzezianska-Lasota ◽  
Marta Michalska-Kasiczak ◽  
Pawel Bazela ◽  
...  
Keyword(s):  
Gene Expression ◽  
Peripheral Blood Mononuclear Cells ◽  
Peripheral Blood ◽  
Wnt Pathway ◽  
Mononuclear Cells ◽  
Peripheral Blood Mononuclear ◽  
Laboratory Parameters ◽  
Expression Levels ◽  
Blood Mononuclear Cells ◽  
Gene Expression Levels

The purpose of the study was to assess the expression of selected genes of the Wnt pathway: APC, AXIN1, CTNNB1, DKK1, GSK3β, KREMEN1, SFRP1, WNT1 in peripheral blood mononuclear cells (PBMC) of patients, selected in consideration of their BMD (bone mineral density) and the occurrence of low-energy fractures. The study involved 45 postmenopausal women, divided into 4 groups, according to BMD and fracture history. Measurements of laboratory parameters and RNA expression in PBMC cells were carried out in material, collected once at the inclusion visit. The densitometric examination was performed on all participants. In the analysis of the relative expression levels (REL) of the studied genes in the entire population, we observed an overexpression for SFRP1 in 100% of samples and WNT1. In addition, the REL of DKK1, APC, and GSK3β genes were slightly elevated vs. the calibrator. In contrast, CTNNB1 and AXIN1 presented with a slightly decreased RELs. Analysis did not show any significant differences among the groups in the relative gene expression levels (p<0.05) of particular genes. However, we have observed quite numerous interesting correlations between the expression of the studied genes and BMD, the presence of fractures, and laboratory parameters, both in the whole studied population as well as in selected groups. In conclusion, the high level of CTNNB1 expression maintains normal BMD and/or protects against fractures. It also appears that the changes in expression levels of the Wnt pathway genes in PBMCs reflect the expected changes in bone tissue.

Sign in / Sign up

Export Citation Format

Share Document